Advocacy Organizations and Emerging Technologies International Summit on Gene Editing Washington, DC 1 December 2015 Sharon F. Terry, MA President & CEO.

Slides:



Advertisements
Similar presentations
PERSONALIZED MEDICINE: Planning for the Future You, Your Biomarkers and Your Rights.
Advertisements

Post Research Benefits Mandika Wijeyaratne MS, MD, FRCS Dept. of Surgery, Colombo.
Retreat Topics iPSC Opportunities in NIAMS Diseases Science Management Forum: Leveraging and Strategic Funding Collaborations Atopic Dermatitis Advancing.
TRANSLATING GENOME WIDE ASSOCIATION STUDIES TO PREVENTION, DIAGNOSTICS, AND THERAPEUTICS Alan E. Guttmacher, M.D. National Human Genome Research Institute.
Influencing Change in Research, Treatment Protocols, and New Drug Development.
1 Genetics The Study of Biological Information. 2 Chapter Outline DNA molecules encode the biological information fundamental to all life forms DNA molecules.
THE HUMAN GENOME PROJECT: IMPLICATIONS FOR HEALTH CARE, RESEARCH AND SOCIETY Washington, DC March 25, 2002 Alan E. Guttmacher, M.D. National Human Genome.
The Impact of the Human Genome Project on Public Health Practice
1 SIMG Florence ppt The Horizons of Predictive Medicine Dr Ian Gilham Worldwide Director, Predictive Medicine Glaxo Wellcome Research and Development.
TSC2 By Samantha Lee. What is it?  Tuberin  TSC1/hamartin  Tumor suppressor (LOH)  41 small exons, 45 kb DNA  5.5 kb mRNA  196 kD.
Centre for Health & Technology Maritta Perälä-Heape, PhD Director, CHT.
Health and Medical Science Nick Besley Manager, Marketing and Communications, Science, Engineering and Health.
The Application of the Scientific Method: Preclinical Trials Copyright PEER.tamu.edu.
3 rd Summer School in Computational Biology September 10, 2014 Frank Emmert-Streib & Salissou Moutari Computational Biology and Machine Learning Laboratory.
An Update in Genetics of Epilepsy
Feasibility and Reliability of Telemedicine Administration of the Unified Batten Disease Rating Scale: A Powerful Tool for Rare Disease Clinical Research.
Prometheus & Myriad The Future of Diagnostic & Gene Claims Mercedes Meyer, Ph.D. Kevin Noonan, Ph.D.
Accessing the Accelerated Approval Pathway with a Rare Neurologic Disease Batten Disease June 29-30, 2010 FDA Public Meeting “Considerations regarding.
C URE T HE P ROCESS 2: Improving the Development Process for Rare Disease Treatments Emil D. Kakkis, M.D., Ph.D. President and Founder October 29, 2014.
FDA Marks Orphan Drug Act Milestone: 30 Year Recognition January 2013.
Genomics and Personalized Care Leming Zhou, PhD Assistant Professor Department of Health Information Management School of Health and Rehabilitation Sciences.
Applications of molecular techniques used in research.
Leveraging Patient Engagement & the Role of Advocacy.
Integrating Scientific Advances into Regulation: Pharmacogenomics and Pharmacogenetics Janet Woodcock, M.D. Director, Center for Drug Evaluation and Research.
1 Batten animal research Network :Lincoln NZ Finnish and Variant Late Infantile Batten Disease David Palmer, Lucy Barry, Hannah Lee, Nadia Mitchell, Janet.
Introduction to Basic Science Emily L. Lowe, Ph.D. Microbiology, Immunology and Molecular Genetics UCLA.
Managing Medical R&D Defining and Realizing Clinical and Commercial Value David J. Wierz Senior Director Commercial Investment & Pricing Strategy Wyeth-Ayerst.
Copyright © The McGraw-Hill Companies, Inc. Permission required for reproduction or display Chapter 20 Genetic Testing, Genetic Counseling, and Gene.
A Third-Party Model for Expanded Access Programs 1. We can deliver large EAPs, far in advance of FDA approval. 2. We can do it in today’s regulatory environment.
 2002 T 1 Second Annual Medical Research Summit The Context of Clinical Research: Challenges and Opportunities March 25, 2002 Washington, DC Leslie A.
MUTATIONS. Mutations Can be beneficial, harmful, neutral Primary source of genetic variation.
Understanding Genetic Testing
Myriad The Future of DNA Claims Mercedes Meyer, Ph.D., JD AIPLA 1.
Meet the Gene Machine Basic Genetics & Background on Genetic Testing.
Consumer Advocate Perspective Clinical Trials Registration Sharon F. Terry, JAM Sharon F. Terry, JAM President and CEO, Genetic Alliance, Inc. Founding.
Cystic Fibrosis (CF) Caroline Wetterauw & Martha Harris.
BATTEN DISEASE Diploma in In-service Education
The Next Generation of Problem Solvers Sharon F. Terry, MA President & CEO Genetic Alliance BIOVISION 24 March 2013.
WHAT IS THE IMPACT OF THE HUMAN GENOME PROJECT FOR DRUG DEVELOPMENT? Arman & Fin.
Direct-to-Consumer Genetic Testing: Outputs from the EASAC-FEAM Working Group Martina Cornel VU University Medical Center, Amsterdam.
I farmaci innovativi in una prospettiva europea Giuseppe M.C. Rosano, MD, PhD Cardiovascular and Cell Sciences Research Institute, St George's University.
Passion is our driver, strategy is our compass May 6, 2016.
Cannabis Stock Market The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce,
© Copyright Neuromed Why Things Are The Way They Are.... Monitoring, Data Chain of Custody, CRFs and Other Mysteries Revealed Christopher C. Gallen, M.D.,
Genes in Life is a place to learn about all the ways genetics is a part of your life. On this site you will learn:   How.
Moiz Bakhiet, MD, PhD, Professor and Chairman
Taxonomy of Strategies
Genomics A Systematic Study of the Locations, Functions and Interactions of Many Genes at Once.
Feasibility and Reliability of Telemedicine Administration of the Unified Batten Disease Rating Scale: A Powerful Tool for Rare Disease Clinical Research.
Dr. Peter John M.Phil, PhD Atta-ur-Rahman School of Applied Biosciences (ASAB) National University of Sciences & Technology (NUST)
Biomedical Therapies Foundation Standard 1: Academic Foundation
Chapter 19 Inborn Errors of Metabolism
Chapter 1 Beginnings of Communication
Basic Genetics & Background on Genetic Testing
Non For Profit Model for Rare Disease Therapy Development
Expert Perspectives on Best Practices for Diagnosis and Management of Spinal Muscular Atrophy.
SMA and Nusinersen (Spinraza) The Story So Far....
Updates in Neuronal Ceroid Lipofuscinosis
Yanggu Shi, Sharon F. Terry, Patrick F. Terry, Lionel G
Psychiatric Disorders: Diagnosis to Therapy
Genetics: From Genes to Genomes
The Study of Biological Information
Progress in Molecular Genetics of Heritable Skin Diseases: The Paradigms of Epidermolysis Bullosa and Pseudoxanthoma Elasticum  Jouni Uitto, Leena Pulkkinen,
Nicholas J. Kramer, Aaron D. Gitler  Neuron 
Updates in Neuronal Ceroid Lipofuscinosis
Heather Adams, PhD University of Rochester Batten Center
Retreat Topics iPSC Opportunities in NIAMS Diseases
Psychiatric Disorders: Diagnosis to Therapy
An Overview of OT for Children
Next Generation Sequencing Market. Report Description and Highlights According to Renub Research market research report “Next Generation Sequencing (NGS)
Presentation transcript:

Advocacy Organizations and Emerging Technologies International Summit on Gene Editing Washington, DC 1 December 2015 Sharon F. Terry, MA President & CEO

Elizabeth and Ian diagnosed with pseudoxanthoma elasticum (PXE) (rare genetic condition: vision loss, cardiovascular, gastro…) Elizabeth Teacher Ian Organic Farmer

BioBank Gene Discovery Patenting Licensing & Intellectual Property Management Human Clinical Trials Drug Screening & Development Approaches Therapeutics --Small Molecules --Nonsense mutants Testing Clinical Diagnostic Test Development via FDA & CLIA Regulatory Strategies

Terry SF, Terry PF, Rauen K, Uitto J, Bercovitch L. Advocacy Organizations as Research Organizations: the PXE International example. Nature Reviews Genetics Feb; Vol. 8, No. 2

Network of thousands of organizations around the world, 1200 of which are disease advocacy organizations. Working to accelerate development and access to interventions for all conditions driven by patients/participants/consumers

Advocacy Orgs As heterozygous as the diseases Kitchen table – Mini-pharma companies Rare – common Various inheritance: AR, AD, mtDNA Prenatal, newborn, childhood, adult Variable morbidity Support – research focus Grasstops – grassroots

Informal Poll Hell, yes! The only way we will make any progress to have a better outcome for our community is with gene editing. Fully explore this – scientifically, ethically. Gene what? Let’s not think about it until the technology is perfected.

One example: Batten’s Disease Antisense Oligonucleotides for the Treatment of Juvenile Neuronal Ceroid Lipofuscinosis (CLN3) Principal Investigator: Michelle Hastings, Ph.D., Rosalind Franklin School of Medicine and Science $50,000, BDSRA CLN3 is most commonly caused by a 1.02kb deletion that encompass 2 exons—7 and 8. The loss of these exons causes ‘misreading’ of the mRNA and ultimately not allowing whole bodily systems to work correctly. This research seeks to correct the way the mRNA functions fixing the string of proteins that affect CLN3.

To edit or not? What is a condition/disease/problem? –Intersex –Deafness –Klinefelter’s syndrome –Turner’s syndrome –Achondroplasia –Weight –Height –Intelligence –Social interaction

Tempered Urgency Needs are enormous and immediate Technical and ethical issues must be resolved satisfactorily Accessible technology Data sharing and transparency to accelerate progress Regulatory dialogue concurrent with technology development

Hope, not hype. 11 Sharon F. Terry, MA